Provided by Tiger Trade Technology Pte. Ltd.

Vertex, Inc.

12.34
-0.4100-3.22%
Post-market: 12.340.00000.00%16:10 EST
Volume:4.21M
Turnover:52.36M
Market Cap:1.97B
PE:308.50
High:13.26
Open:12.81
Low:12.23
Close:12.75
52wk High:48.00
52wk Low:11.96
Shares:159.53M
Float Shares:70.11M
Volume Ratio:0.90
T/O Rate:6.01%
Dividend:- -
Dividend Rate:- -
EPS(TTM):0.0400
EPS(LYR):0.0400
ROE:3.29%
ROA:-0.40%
PB:7.60
PE(LYR):308.50

Loading ...

Vertex Pharmaceuticals Is Maintained at Buy by HC Wainwright & Co.

Dow Jones
·
Yesterday

HC Wainwright Adjusts Price Target on Vertex Pharmaceuticals to $591 From $518, Maintains Buy Rating

MT Newswires Live
·
Yesterday

Vertex Pharmaceuticals price target raised to $591 from $518 at H.C. Wainwright

TIPRANKS
·
Yesterday

Vertex Pharmaceuticals (VRTX) Gets a Buy from Barclays

TIPRANKS
·
Yesterday

Why Vertex Pharmaceuticals (VRTX) Is Up 6.0% After Profit Rebound And Non-CF Pipeline Update - And What's Next

Simply Wall St.
·
Yesterday

Vertex Minerals Secures New South Wales Exploration License; Shares Hit Over One-Year Low

MT Newswires Live
·
Yesterday

Vertex, Inc. Earnings Call Highlights Cloud and AI Momentum

TIPRANKS
·
Feb 16

Is Vertex Pharmaceuticals (VRTX) Still Attractive After Strong Multi Year Share Price Gains

Simply Wall St.
·
Feb 15

Analysts’ Opinions Are Mixed on These Healthcare Stocks: Vertex Pharmaceuticals (VRTX) and 10x Genomics (TXG)

TIPRANKS
·
Feb 15

Vertex Pharmaceuticals Inc. Stock Rallies 5.7%, Outperforms Peers

Dow Jones
·
Feb 14

Vertex Pharmaceuticals Up Over 6%, On Track for Highest Close Since May 2025 -- Data Talk

Dow Jones
·
Feb 14

Vertex Pharmaceuticals Q4 'Anticlimactic' on Pipeline, 2026 Guide Reinforces Core Strength, RBC Says

MT Newswires Live
·
Feb 14

Vertex Pharmaceuticals' Therapies for Kidney Diseases Could Diversify Long-Term Revenue Streams, Oppenheimer Says

MT Newswires Live
·
Feb 14

Analysts Have Conflicting Sentiments on These Healthcare Companies: Organon (OGN), Maravai Lifesciences Holdings (MRVI) and Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Feb 13

Vertex Pharmaceuticals price target raised to $558 from $495 at Scotiabank

TIPRANKS
·
Feb 13

Vertex Pharmaceuticals (VRTX) Receives a Buy from Evercore ISI

TIPRANKS
·
Feb 13

Morgan Stanley Sticks to Their Buy Rating for Vertex Pharmaceuticals (VRTX)

TIPRANKS
·
Feb 13

Scotiabank Adjusts Vertex Pharmaceuticals PT to $558 From $495, Maintains Sector Outperform Rating

MT Newswires Live
·
Feb 13

Vertex Pharmaceuticals Revenue Climbs on Continued Cystic Fibrosis Demand

Dow Jones
·
Feb 13

Vertex Pharmaceuticals Q4 Adj. EPS $5.03 Misses $5.07 Estimate, Sales $3.190B Beat $3.176B Estimate

Benzinga
·
Feb 13